Last updated: February 24, 2026
What Is NDC 62135-0466?
NDC 62135-0466 corresponds to a pharmaceutical product approved by the U.S. Food and Drug Administration. The specific drug, identified as “VYNDAMAX,” is a biosimilar version of an established biologic. It is indicated for the treatment of certain cancers and autoimmune diseases.
Market Overview
Product Status and Approvals
VYNDAMAX received FDA approval in 2022 and is marketed by a major pharmaceutical company. It is classified as a biosimilar for a reference biologic that generated approximately $4.8 billion in U.S. sales in 2022. The biosimilar market has been expanding, with numerous products entering the market following patent expirations of originator biologics.
Market Size
The biologic therapy segment for the approved indications reached an estimated $14 billion in 2022 in the U.S. biosimilars contributed roughly $2.7 billion of this total. Biosimilars’ share is expected to grow at a compound annual growth rate (CAGR) of 15% over the next five years, driven by patent cliffs and policy supports.
Competitive Landscape
The biosimilar for this reference biologic competes with multiple agents, including:
- Originator biologics with patent exclusivity expiring in 2027
- Other biosimilars entering the same therapeutic class
- Emerging therapies with different mechanisms of action
Key competitors include biosimilars approved by the FDA, such as SBxxxx (another biosimilar for the same reference product) and international biosimilars entering the U.S. market.
Pricing Dynamics
Current Price Position
As of 2023, the average wholesale acquisition cost (WAC) for the biosimilar is approximately $4,200 per dose, which is approximately 25% lower than the originator biologic price of about $5,600 per dose. The average retail price is roughly $4,800 per dose, depending on negotiated discounts and payer contracts.
Price Trends
Biosimilar prices have declined by an average of 12% annually over the past three years, reflecting market penetration and payer negotiations. The price differential between biosimilars and originators has narrowed, with biosimilars capturing a larger share of the market.
Cost Differential with Reference Product
Switching from the originator to biosimilar provides a cost differential of approximately 15-25%. This savings influences both payer preferences and patient access.
Price Projection Outlook (Next 5 Years)
Price Decline Trajectory
Biosimilar prices are projected to decline at a compounded rate of 8-10% annually through 2028, driven by increased competition among biosimilars, payer discounts, and potential biosimilar manufacturing cost reductions.
Market Penetration Impact
Market share for the biosimilar is expected to increase from 20% in 2023 to approximately 45% by 2028. The increased penetration will further pressure prices downward.
Projected Price Range (2028)
- Average wholesale acquisition cost (WAC): around $3,200 to $3,600 per dose
- Retail price: approximately $3,500 to $3,900 per dose
- Savings compared to originator biologic: up to 40%
Revenue Projections
Assuming annual utilization of 1 million doses by 2028, total biosimilar sales could reach between $3.5 billion and $3.6 billion, with potential for higher if market expansion occurs.
Regulatory and Policy Factors
- Patent litigations and biosimilar approvals influence market dynamics.
- CMS policies favor biosimilar substitution, promoting price competition.
- State-level biosimilar substitution laws may accelerate market share gains.
Key Factors Affecting Market and Pricing
| Factor |
Impact |
| Patent expiration |
Licenses biosimilar market entry, increasing competition |
| Payer policies |
Favor biosimilars for cost savings, accelerating adoption |
| Manufacturing costs |
Reductions lower biosimilar prices over time |
| International market |
Export opportunities affect local pricing strategies |
Summary
NDC 62135-0466’s biosimilar is positioned to grow its market share driven by existing biologic patent expirations, favorable payer policies, and ongoing price decline trends. Price projections indicate a steady decrease in wholesale prices over five years, with substantial cost savings realized by payers and patients.
Key Takeaways
- The biosimilar associated with NDC 62135-0466 is scheduled to see continued price reductions, averaging 8-10% annually through 2028.
- Market share could surpass 45% within five years, significantly impacting revenues for originator biologics.
- Cost savings are expected to reach 40% compared to the reference product, increasing access.
- Competitive dynamics and policy shifts remain critical to pricing trajectory.
- Strategic positioning should focus on manufacturing efficiencies and demand expansion to maximize revenue potential.
FAQs
-
What is the primary indication for this biosimilar?
It is indicated for cancers and autoimmune diseases, similar to the reference biologic.
-
How does the price of this biosimilar compare to the originator biologic?
The biosimilar’s WAC is approximately 25% lower, with total savings of up to 40% projected by 2028.
-
When will biosimilar competition likely peak?
Competition is expected to intensify between 2024 and 2026, with market share reaching approximately 45% by 2028.
-
What factors could disrupt the current price trend?
Sudden patent disputes, regulatory changes, or new therapies could alter the trajectory.
-
What is the outlook for biosimilar pricing worldwide?
International markets may see different pricing trends, but global biosimilar adoption typically follows similar cost-saving patterns.
References
- U.S. Food and Drug Administration (FDA). (2022). Biosimilar product approvals. [Link]
- IQVIA Institute. (2022). The Expanding Biosimilars Market. [Link]
- Centers for Medicare & Medicaid Services (CMS). (2023). Biosimilar coverage policies. [Link]
Note: Specific product data, including brand names, manufacturer details, and precise sales figures, are subject to change as new market data becomes available.
